StockData
ANI Pharmaceuticals Inc logo

ANI Pharmaceuticals Inc (ANIP) stock

ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$69.99−0.90 (-1.27%)

Close on Nov 17, 2026Market cap $1.61BP/E 14.9Yield –

ANI Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

ANI Pharmaceuticals's cash was $360.21M at Jun 30, 2026. For fiscal 2025 it was $285.59M, up 97.1% from the year before. Over ten years it grew 6.3% a year on average. The highest annual figure on record is $285.59M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$285.59M+97.1%
FY2024Dec 31, 2024$144.89M-34.5%
FY2023Dec 31, 2023$221.12M+358.5%
FY2022Dec 31, 2022$48.23M-51.9%
FY2021Dec 31, 2021$100.30M+1175.4%
FY2020Dec 31, 2020$7.86M-87.4%
FY2019Dec 31, 2019$62.33M+44.9%
FY2018Dec 31, 2018$43.01M+38.1%
FY2017Dec 31, 2017$31.14M+13.8%
FY2016Dec 31, 2016$27.37M-82.3%
FY2015Dec 31, 2015$154.68M-8.5%
FY2014Dec 31, 2014$169.04M+1422.2%
FY2013Dec 31, 2013$11.11M+100854.5%
FY2012Dec 31, 2012$11.00K–
FY2011Dec 31, 2011$0-100.0%
FY2010Dec 31, 2010$38.16M+27.8%
FY2009Dec 31, 2009$29.86M+153.9%
FY2008Dec 31, 2008$11.76M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$360.21M+65.4%
Q1 FY2026Mar 31, 2026$311.18M+107.7%
Q4 FY2025Dec 31, 2025$285.59M+97.1%
Q3 FY2025Sep 30, 2025$262.61M+81.1%
Q2 FY2025Jun 30, 2025$217.83M-9.3%
Q1 FY2025Mar 31, 2025$149.80M-34.5%
Q4 FY2024Dec 31, 2024$144.89M-34.5%
Q3 FY2024Sep 30, 2024$144.98M-24.9%
Q2 FY2024Jun 30, 2024$240.11M+48.5%
Q1 FY2024Mar 31, 2024$228.60M+237.4%
Q4 FY2023Dec 31, 2023$221.12M+358.5%
Q3 FY2023Sep 30, 2023$193.08M+243.1%
Q2 FY2023Jun 30, 2023$161.71M+155.1%
Q1 FY2023Mar 31, 2023$67.76M-11.9%
Q4 FY2022Dec 31, 2022$48.23M-51.9%
Q3 FY2022Sep 30, 2022$56.28M+269.0%
Q2 FY2022Jun 30, 2022$63.39M+161.3%
Q1 FY2022Mar 31, 2022$76.91M+206.7%
Q4 FY2021Dec 31, 2021$100.30M+1175.4%
Q3 FY2021Sep 30, 2021$15.25M-14.8%
Q2 FY2021Jun 30, 2021$24.26M-12.4%
Q1 FY2021Mar 31, 2021$25.07M+22.8%
Q4 FY2020Dec 31, 2020$7.86M-87.4%
Q3 FY2020Sep 30, 2020$17.90M-70.0%
Q2 FY2020Jun 30, 2020$27.70M-31.7%
Q1 FY2020Mar 31, 2020$20.41M-46.6%
Q4 FY2019Dec 31, 2019$62.33M+44.9%
Q3 FY2019Sep 30, 2019$59.67M+35.2%
Q2 FY2019Jun 30, 2019$40.59M-26.2%
Q1 FY2019Mar 31, 2019$38.23M-26.4%
Q4 FY2018Dec 31, 2018$43.01M+38.1%
Q3 FY2018Sep 30, 2018$44.14M+144.8%
Q2 FY2018Jun 30, 2018$54.99M+557.1%
Q1 FY2018Mar 31, 2018$51.97M+380.0%
Q4 FY2017Dec 31, 2017$31.14M+13.8%
Q3 FY2017Sep 30, 2017$18.03M+11.6%
Q2 FY2017Jun 30, 2017$8.37M–
Q1 FY2017Mar 31, 2017$10.83M–
Q4 FY2016Dec 31, 2016$27.37M–
Q3 FY2016Sep 30, 2016$16.16M–

More ANI Pharmaceuticals figures

See a number that looks wrong?